A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.

A new method with a low pH step to dissociate serum complexes has been developed to measure serum levels of antigens associated with ovarian cancer. The antigens are detected by monoclonal antibodies HMFG1 and HMFG2 and have been compared to an existing ovarian cancer associated antigen detected by...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhokia, B., Canney, P. A., Pectasides, D., Munro, A. J., Moore, M., Wilkinson, P. M., Self, C., Epenetos, A. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1986
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001608/
https://www.ncbi.nlm.nih.gov/pubmed/3467785
_version_ 1782135639527915520
author Dhokia, B.
Canney, P. A.
Pectasides, D.
Munro, A. J.
Moore, M.
Wilkinson, P. M.
Self, C.
Epenetos, A. A.
author_facet Dhokia, B.
Canney, P. A.
Pectasides, D.
Munro, A. J.
Moore, M.
Wilkinson, P. M.
Self, C.
Epenetos, A. A.
author_sort Dhokia, B.
collection PubMed
description A new method with a low pH step to dissociate serum complexes has been developed to measure serum levels of antigens associated with ovarian cancer. The antigens are detected by monoclonal antibodies HMFG1 and HMFG2 and have been compared to an existing ovarian cancer associated antigen detected by the antibody CA125. Elevated HMFG1 was found in 56%, and elevated HMFG2 in 65% of 924 sera from 85 patients with ovarian cancer. CA125 was elevated in 85% of these sera. When the three markers were used in conjunction, 95% of sera from patients with ovarian cancer were positive--compared with 7% in sera from healthy control subjects. Therefore, the combination of HMFG1, HMFG2 and CA125 increases the diagnostic accuracy. If all three markers are normal in a patient previously treated for ovarian cancer then no further positive information regarding disease status can be obtained by ultrasound and CT scanning.
format Text
id pubmed-2001608
institution National Center for Biotechnology Information
language English
publishDate 1986
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20016082009-09-10 A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer. Dhokia, B. Canney, P. A. Pectasides, D. Munro, A. J. Moore, M. Wilkinson, P. M. Self, C. Epenetos, A. A. Br J Cancer Research Article A new method with a low pH step to dissociate serum complexes has been developed to measure serum levels of antigens associated with ovarian cancer. The antigens are detected by monoclonal antibodies HMFG1 and HMFG2 and have been compared to an existing ovarian cancer associated antigen detected by the antibody CA125. Elevated HMFG1 was found in 56%, and elevated HMFG2 in 65% of 924 sera from 85 patients with ovarian cancer. CA125 was elevated in 85% of these sera. When the three markers were used in conjunction, 95% of sera from patients with ovarian cancer were positive--compared with 7% in sera from healthy control subjects. Therefore, the combination of HMFG1, HMFG2 and CA125 increases the diagnostic accuracy. If all three markers are normal in a patient previously treated for ovarian cancer then no further positive information regarding disease status can be obtained by ultrasound and CT scanning. Nature Publishing Group 1986-12 /pmc/articles/PMC2001608/ /pubmed/3467785 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Dhokia, B.
Canney, P. A.
Pectasides, D.
Munro, A. J.
Moore, M.
Wilkinson, P. M.
Self, C.
Epenetos, A. A.
A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
title A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
title_full A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
title_fullStr A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
title_full_unstemmed A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
title_short A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.
title_sort new immunoassay using monoclonal antibodies hmfg1 and hmfg2 together with an existing marker ca125 for the serological detection and management of epithelial ovarian cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001608/
https://www.ncbi.nlm.nih.gov/pubmed/3467785
work_keys_str_mv AT dhokiab anewimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT canneypa anewimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT pectasidesd anewimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT munroaj anewimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT moorem anewimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT wilkinsonpm anewimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT selfc anewimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT epenetosaa anewimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT dhokiab newimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT canneypa newimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT pectasidesd newimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT munroaj newimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT moorem newimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT wilkinsonpm newimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT selfc newimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer
AT epenetosaa newimmunoassayusingmonoclonalantibodieshmfg1andhmfg2togetherwithanexistingmarkerca125fortheserologicaldetectionandmanagementofepithelialovariancancer

Ejemplares similares